Lexicon Pharmaceuticals vs Ocular Therapeutix
Ocular Therapeutix reported revenue of $52 million in fiscal 2025, about the same as Lexicon Pharmaceuticals' $50 million in fiscal 2025. Lexicon Pharmaceuticals' revenue grew 60.2% in its latest year, and Ocular Therapeutix's fell 18.5%. Lexicon Pharmaceuticals had an operating margin of -98.2%, against -519.8% at Ocular Therapeutix. Free cash flow was −$68 million at Lexicon Pharmaceuticals and −$217 million at Ocular Therapeutix.
Side by side
| Lexicon Pharmaceuticals | Ocular Therapeutix | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $50M | $52M |
| Revenue growth | 60.2% | −18.5% |
| Revenue growth a year, last 5 years | 15.7% | 24.5% |
| Gross margin | 99.5% | 87.3% |
| Operating margin | −98.2% | −519.8% |
| Net margin | −101.1% | −511.9% |
| Free cash flow | −$68M | −$217M |
| Free cash flow margin | −136.2% | −417.5% |
| Return on capital | −105.0% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 13.4% | 18.3% |
| Last close | $1.67 | $5.86 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $2.7 million, sold $0 | bought $461,354, sold $2.8 million |
| Piotroski F-score | 4 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Lexicon PharmaceuticalsOcular Therapeutix
Operating margin
Percent of revenue
Lexicon PharmaceuticalsOcular Therapeutix
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Lexicon PharmaceuticalsOcular Therapeutix
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lexicon Pharmaceuticals and Ocular Therapeutix pages.